Program
infigratinib
Also written as “Infigratinib”, “BGJ398” and “infigratinib 0.128 mg/kg/day”.
Its studies are mostly in Achondroplasia · Mucopolysaccharidosis IV · Stomach Neoplasms · Cholangiocarcinoma · Urinary Bladder Neoplasms, led by 5 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BridgeBio | 83 open or running | phase 3since Dec 10, 2018 | May 12, 2014 | Jan 2027phase 3 · NCT06873035 |
| Novartis | 50 open or running | phase 2since Oct 28, 2013 | Oct 27, 2009 | none ahead |
| LianBio | 20 open or running | phase 2since Jul 28, 2021 | Jul 28, 2021 | none ahead |
| Helsinn Healthcare | 10 open or running | phase 2since Jan 12, 2022 | Jan 12, 2022 | none ahead |
| Pfizer | 10 open or running | phase 2since Apr 28, 2014 | Apr 28, 2014 | none ahead |
Also a collaborator on its studies: labcorp-corporation-of-america-holdings-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 3 studies since Oct 27, 2009.
- Oct 28, 2013Phase 2 study in GlioblastomaNovartis · NCT01975701 · 26 enrolled · United States, Australia, Belgium and more
- Apr 28, 2014Pfizer's first study: phase 2 study in MelanomaNew to PfizerPfizer · NCT02159066 · 158 enrolled · United States, Australia, Canada and more
- May 12, 2014BridgeBio's first study: phase 2 study in CholangiocarcinomaNew to BridgeBioBridgeBio · NCT02150967 · 143 enrolled · United States, Belgium, Germany and more
- Jun 6, 2014Phase 2 study in Hematologic NeoplasmsNovartis · NCT02160041 · 84 enrolled · United States
- Dec 10, 2018Phase 3 study in CholangiocarcinomaBridgeBio · NCT03773302 · 48 enrolled · United States, Australia, Belgium and more
- Dec 2, 2019Phase 3 study in Upper Tract Urothelial CarcinomasBridgeBio · NCT04197986 · 39 enrolled · United States, Belgium, Bulgaria and more
- Jan 29, 2020Phase 2 study in AchondroplasiaBridgeBio · NCT04265651 · 84 enrolled · United States, Australia, Canada and more
- Jul 28, 2021LianBio's first study: phase 2 study in Stomach NeoplasmsNew to LianBioLianBio · NCT05019794 · 80 enrolled · China
- Nov 22, 2021Phase 2 study in AchondroplasiaBridgeBio · NCT05145010 · 325 planned · United States, Argentina, Australia and more
- Jan 12, 2022Helsinn Healthcare's first study: phase 2 study in Central Nervous System NeoplasmsNew to Helsinn HealthcareHelsinn Healthcare · NCT05222165 · United States, Canada, Germany
- Nov 29, 2023Phase 2 study in Stomach NeoplasmsLianBio · NCT06206278 · 6 enrolled · China
- Nov 29, 2023Phase 3 study in AchondroplasiaBridgeBio · NCT06164951 · 114 enrolled · United States, Argentina, Australia and more
- Feb 18, 2025Phase 3 study in HypochondroplasiaBridgeBio · NCT06873035 · 24 planned · United States, Australia, Canada and more
- Jan 19, 2026Phase 2 study in HypochondroplasiaBridgeBio · NCT07393373 · 135 planned · United States, Australia, Canada and more
Ahead
- Jan 2027Primary completion: phase 3 study in HypochondroplasiaBridgeBio · NCT06873035
- Dec 1, 2031Primary completion: phase 2 study in AchondroplasiaBridgeBio · NCT05145010
- May 31, 2036Primary completion: phase 2 study in HypochondroplasiaBridgeBio · NCT07393373
TargetBeta
“Fibroblast growth factor receptor inhibitor; Fibroblast growth factor receptor inhibitor”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| nintedanibrule | Boehringer Ingelheim | phase 4 | 76 |
| futibatinibrule | Otsuka | phase 3 | 10 |
Studies
All 17 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07393373Hypochondroplasia · United States, Australia, Canada and more | 2 | By invitation | BridgeBio | May 31, 2036 | 135 |
| NCT06873035Hypochondroplasia · United States, Australia, Canada and more | 3 | By invitation | BridgeBio | Jan 2027 | 24 |
| NCT06206278Stomach Neoplasms · China | 2 | Terminated | LianBio | May 31, 2024 | 6 |
| NCT06164951Achondroplasia · United States, Argentina, Australia and more | 3 | Completed | BridgeBio | Dec 18, 2025 | 114 |
| NCT05222165Central Nervous System Neoplasms · United States, Canada, Germany | 2 | Withdrawn | Helsinn Healthcare | Dec 16, 2022 | 0 |
| NCT05145010Achondroplasia · United States, Argentina, Australia and more | 2 | By invitation | BridgeBio | Dec 1, 2031 | 325 |
| NCT05019794Stomach Neoplasms · China | 2 | UNKNOWN | LianBio | Dec 30, 2022 | 80 |
| NCT04265651Achondroplasia · United States, Australia, Canada and more | 2 | Completed | BridgeBio | Oct 21, 2024 | 84 |
| NCT04197986Upper Tract Urothelial Carcinomas · United States, Belgium, Bulgaria and more | 3 | Terminated | BridgeBio | Feb 28, 2023 | 39 |
| NCT03773302Cholangiocarcinoma · United States, Australia, Belgium and more | 3 | Terminated | BridgeBio | Mar 2, 2023 | 48 |
| NCT02160041Hematologic Neoplasms · United States | 2 | Terminated | Novartis | Apr 30, 2018 | 84 |
| NCT02150967Cholangiocarcinoma · United States, Belgium, Germany and more | 2 | Terminated | BridgeBio | Mar 1, 2021 | 143 |
| NCT02159066Melanoma · United States, Australia, Canada and more | 2 | Completed | Pfizer | Jan 10, 2023 | 158 |
| NCT01975701Glioblastoma · United States, Australia, Belgium and more | 2 | Completed | Novartis | Oct 3, 2018 | 26 |
| NCT01928459Breast Neoplasms · United States, Australia, Belgium and more | 1 | Completed | Novartis | Aug 2016 | 62 |
| NCT01697605Tumor With Alterations of the FGF-R · China, Japan | 1 | Completed | Novartis | Feb 7, 2019 | 9 |
| NCT01004224Lung Neoplasms · United States, Australia, Austria and more | 1 | Completed | Novartis | Oct 8, 2018 | 208 |
How it is read
Names in the registry
- “Infigratinib”, 7 entries
- “BGJ398”, 7 entries
- “infigratinib 0.128 mg/kg/day”, 1 entry
- “infigratinib 0.25 mg/kg/day”, 1 entry
- “Infigratinib 0.25 mg/kg/day”, 1 entry
Conditions, from the studies’ own filings
- Achondroplasia, 3 studies
- Mucopolysaccharidosis IV, 2 studies
- Stomach Neoplasms, 2 studies
- Cholangiocarcinoma, 2 studies
- Urinary Bladder Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.